{
    "nct_id": "NCT04543305",
    "official_title": "A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* Adequate organ function (bone marrow, hepatic, renal, cardiovascular)\n* Left ventricular ejection fraction of ≥50%\n* Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use a highly effective method of contraception during the trial\n* Patients must have recovered from the effects of any prior cancer related therapy, radiotherapy or surgery (toxicity ≤ Grade 1)\n* All patients on prior investigational agents must wait at least 5 half-lives of the agent in question, or 14 days, whichever is longer before study entry\n* AML patients only: Pathologically confirmed diagnosis of AML as defined by the WHO Classification and patients with targeted mutations must have been treated with appropriate therapy for their disease\n\n  * White blood cell count < 25 x 10^9/L. Hydrea or leukapheresis are permitted to meet this criterion.\n* CMML patients only: intermediate-2 or high risk per CMML-specific prognostic scoring system (CPSS) or clinical/molecular CPSS (CPSS-mol) criteria. Must have failed prior therapy with a hypomethylating agent.\n* MDS patients only: Intermediate, high, or very high risk by International Prognostic Scoring System-Revised [IPSS-R] criteria that is relapsed or refractory to approved therapies or MDS/MPN Overlap Syndrome (displaying both fibrosis and dysplastic features).\n* NHL patients only: Histologically or cytologically confirmed NHL, including B- and T-cell lymphomas that is relapsed or refractory or intolerant to approved therapies. Must have one lesion that can be measured for response\n* MM patients only: Measurable disease defined by one or more of the following: Serum M-protein ≥ 0.5 g/dL, Urine M-protein ≥ 200 mg/24 hours, Serum Free Light Chain (sFLC) > 10 mg/dL with normal serum FLC ratio. Presence of soft tissue plasmacytoma confirmed by imaging\n* NHL and MM patients only: must have the following lab values within 14 days prior to study Day 1:\n\n  * ANC ≥1.0 x 10^3 μL\n  * Platelet count ≥50,000 μL\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known hypersensitivity to any of the components of PRT1419\n* Female patients who are pregnant or lactating\n* Mean QTcF interval of >480 msec\n* History of heart failure, additional risk factors for arryhthmias or requiring concomitant medications that prolong the QT/QTc interval\n* Hematopoietic stem-cell transplant < 90 days or have GVHD Grade >1 at study entry\n* Uncontrolled intercurrent illnesses\n* Treatment with strong inhibitors of CYP2C8 and/or P-glycoprotein for which there are no therapeutic substitutions\n* Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption\n* HIV positive; known active hepatitis B or C\n* Prior exposure to an MCL1 inhibitor\n* History of another malignancy except:\n\n  * Malignancy treated with curative intent with no known active disease for >2 years at study entry\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease\n  * Other concurrent low-grade malignancies (i.e chronic lymphocytic leukemia (Rai 0)) may be considered after consultation with Sponsor.",
    "miscellaneous_criteria": ""
}